Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? (Q35830496)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

24 August 2020

Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

7 November 2019

1 reference

24 August 2020

1 reference

24 August 2020

1 reference

24 August 2020

Aliana Guerrieri Gonzaga

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Massimiliano Cazzaniga

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Clara Varricchio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Chiara Montefrancesco

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Irene Feroce

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

5 March 2012

10 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

22 June 2019

17 June 2019

7 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

29 May 2020

24 August 2020

Journal of Biomedicine and Biotechnology

10 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

22 June 2019

17 June 2019

7 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

29 May 2020

24 August 2020

2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

172897

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

28 January 2020

copyright license

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

The unhydrolyzable fenretinide analogue 4-hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase- dependent and independent of the retinoic acid receptor

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Retinoids interfere with the AP1 signalling pathway in human breast cancer cells.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Hydrolysis of 4-HPR to atRA occurs in vivo but is not required for retinamide-induced apoptosis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Retinoid therapy of high-risk neuroblastoma.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Retinoids and their receptors in cancer development and chemoprevention

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Retinoic acid and 4-hydroxyphenylretinamide induce growth inhibition and tissue transglutaminase through different signal transduction pathways in mouse fibroblasts (NIH 3T3 cells).

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

A decade of molecular biology of retinoic acid receptors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Nuclear receptor/AP-1 interaction

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Distribution of fenretinide in the mammary gland of breast cancer patients

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Effects of meals and meal composition on the bioavailability of fenretinide

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4‐HPR

11 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

Role of antioxidants and intracellular free radicals in retinamide-induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

Effect of fenretinide on ovarian carcinoma occurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

The insulin-like growth factor I receptor: a key to tumor growth?

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Inhibition of carcinogenesis by retinoids.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3303873

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

24 September 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F172897

Tamoxifen and fenretinide in women with metastatic breast cancer

21 January 2018

1 reference

12 December 2020

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer

1 reference

12 December 2020

Can fenretinide protect women against ovarian cancer?

1 reference

12 December 2020

Clinical development plan: N-(4-hydroxyphenyl)retinamide

1 reference

12 December 2020

Retinoids and apoptosis: implications for cancer chemoprevention and therapy

1 reference

12 December 2020

Effects of endogenously activated transforming growth factor-beta on growth and differentiation of retinoic acid-treated HL-60 cells

1 reference

12 December 2020

Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer

1 reference

12 December 2020

Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients

1 reference

12 December 2020

Tolerability of the synthetic retinoid Fenretinide (HPR)

1 reference

12 December 2020

Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients

1 reference

12 December 2020

The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/172897

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

release_e6shrqf6bbdffp7e6jvlgvjwwi

28 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e6shrqf6bbdffp7e6jvlgvjwwi

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

PubMed publication ID

22500077

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22500077%20AND%20SRC:MED&resulttype=core&format=json